IBI305

IBI305 is available at approximately 30% lower cost than the originator bevacizumab product (Avastin) in Chinese healthcare settings. Dose modification of IBI305 is generally not recommended as a strategy for managing adverse events. Evidence from ORIENT-32 and ORIENT-31 demonstrates that the sintilimab-IBI305 combination is safe and effective across multiple solid tumour types. IBI305 is a bevacizumab biosimilar developed in China with domestic regulatory approval and coverage under China's national insurance scheme. If IBI305 is stopped for any reason, continuation of sintilimab may be considered following thorough physician evaluation of the patient's status. The most commonly reported adverse effects of IBI305 in prior clinical trials are hypertension and epistaxis.